Following its annual general meeting, Sweden’s Orexo is to repurchase 500,000 of its shares at their market value.
The firm said the purpose of the share repurchases is to promote efficient capital usage and provide flexibility on the distribution of capital to shareholders.
The share repurchase program will be managed by Danske Bank.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze